{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:40:39Z","timestamp":1786718439077,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/0973-1482.187384","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"957","source":"Crossref","is-referenced-by-count":3,"title":["Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis"],"prefix":"10.4103","volume":"14","author":[{"given":"Zhansheng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhensong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.187384-1","first-page":"3271","volume-title":"Metastatic behavior of breast cancer subtypes","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-2","first-page":"88","volume-title":"Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment","author":"Berman","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"key-10.4103\/0973-1482.187384-3","doi-asserted-by":"crossref","unstructured":"Khodari W, Sedrati A, Naisse I, Bosc R, Belkacemi Y; AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa; www.aromecancer.org). Impact of loco-regional treatment on metastatic breast cancer outcome: A review. Crit Rev Oncol Hematol 2013;87:69-79.","DOI":"10.1016\/j.critrevonc.2012.12.005"},{"key":"key-10.4103\/0973-1482.187384-4","first-page":"489","volume-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","author":"Cardoso","year":"2014","journal-title":"Breast"},{"key":"key-10.4103\/0973-1482.187384-5","first-page":"533","volume-title":"Treatment options for breast cancer resistant to anthracycline and taxane","author":"Moreno-Aspitia","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/0973-1482.187384-6","first-page":"536","volume-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer","author":"Fumoleau","year":"2004","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0973-1482.187384-7","first-page":"5210","volume-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-8","first-page":"177","volume-title":"Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy","author":"Clemons","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/0973-1482.187384-9","first-page":"3256","volume-title":"Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","author":"Sparano","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-10","first-page":"121","volume-title":"Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer","author":"Barrios","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/0973-1482.187384-11","first-page":"792","volume-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-12","first-page":"1164","volume-title":"Amulticenter randomized phase III trial of vinorelbine\/gemcitabine doublet versus capecitabine monotherapy in anthracycline-and taxane-pretreated women with metastatic breast cancer","author":"Pallis","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.187384-13","first-page":"2870","volume-title":"Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer","author":"Crown","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-14","first-page":"594","volume-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-15","first-page":"1","volume-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"key-10.4103\/0973-1482.187384-16","first-page":"725","volume-title":"Phase II clinical trial of ixabepilone in metastatic cervical carcinoma","author":"Burotto","year":"2015","journal-title":"Oncologist"},{"key":"key-10.4103\/0973-1482.187384-17","first-page":"37","volume-title":"Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer","author":"Stathopoulos","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-18","first-page":"310","volume-title":"Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes","author":"Toi","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-19","first-page":"360","volume-title":"Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer","author":"Seo","year":"2011","journal-title":"Invest New Drugs"},{"key":"key-10.4103\/0973-1482.187384-20","first-page":"5760","volume-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res"},{"key":"key-10.4103\/0973-1482.187384-21","first-page":"914","volume-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"key-10.4103\/0973-1482.187384-22","first-page":"716","volume-title":"Progress on using bevacizumab in treating triple-negative breast ancer","author":"Pan","year":"2015","journal-title":"Chin J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-23","first-page":"4286","volume-title":"RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.187384-24","first-page":"1269","volume-title":"Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial","author":"von","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0973-1482.187384-25","first-page":"2666","volume-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.187384-26","first-page":"7462","volume-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"key-10.4103\/0973-1482.187384-27","first-page":"77","volume-title":"Aphase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors","author":"Camidge","year":"2008","journal-title":"Anticancer Drugs"},{"key":"key-10.4103\/0973-1482.187384-28","first-page":"e287","volume-title":"Characterization of durable responder for capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer","author":"Hong","year":"2015","journal-title":"Clin Breast Cancer"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:35:09Z","timestamp":1786714509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0973-1482.187384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"alternative-id":["187384"],"URL":"https:\/\/doi.org\/10.4103\/0973-1482.187384","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}